Prediction of BRCA2-association in hereditary breast carcinomas using array-CGH

Area of Science:

• Genomics
• Oncology
• Cancer Genetics

Background:

• Germline mutations in BRCA1/2 significantly elevate lifetime risk for breast and ovarian cancers.
• Accurate identification of these mutations is crucial for treatment decisions and family screening.
• Current diagnostics face challenges in identifying all BRCA2-associated cases and classifying variants of unknown significance (VUS).

Purpose of the Study:

• To develop a genomic signature-based test for identifying BRCA2-associated breast tumors.
• To improve diagnostic accuracy and aid in the clinical management of hereditary breast and ovarian cancer (HBOC) cases.

Main Methods:

• A BRCA2-classifier was developed using array comparative genomic hybridization (array-CGH) profiles from BRCA2-mutated and sporadic breast tumors.
• The classifier was validated on an independent cohort of BRCA2-mutated and sporadic breast tumors.
• The classifier was applied to 89 breast tumors from HBOC families with negative or VUS results from routine diagnostics.

Main Results:

• The classifier achieved 89% sensitivity and 84% specificity on the validation set.
• Of 89 HBOC cases, 17 exhibited a BRCA2-like genomic profile, with three showing additional signs of BRCA2 deficiency.
• Specific chromosomal aberrations, including loss on 13q and 14q, and gain on 17q, were characteristic of BRCA2-mutated tumors.

Conclusions:

• The developed BRCA2-classifier can distinguish BRCA2-like tumors from sporadic and BRCA1-like tumors.
• This genomic classification method can serve as an adjunct diagnostic tool for clinicians.
• It assists in decision-making for HBOC patients and in classifying variants of unknown significance.